ONO Pharmaceutical Co. Ltd. and Bristol-Myers Squibb K.K. have received supplemental regulatory approval in Japan for their combination therapy using Opdivo® (nivolumab) and Yervoy® (ipilimumab) for the treatment of unresectable hepatocellular carcinoma $(HCC)$. This approval expands the use of these drugs, based on the positive results from the CheckMate -9DW study, which demonstrated a significant improvement in overall survival compared to lenvatinib or sorafenib monotherapy. The collaboration between ONO and Bristol-Myers Squibb marks a significant advancement in the treatment options for patients with this form of liver cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.